Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Earnings up 76% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
4Q Revenues: $5.5 billion (+7%)

4Q Earnings: $852 million (+76%)

FY Revenues: $21.2 billion (+9%)

FY Earnings: $3.7 billion (+20%)

Comments: U.S. sales increased 8% to $3.6 billion in the quarter and International sales increased 4% to $1.9 billion. Plavix sales were $ 1.7 billion in the quarter (-3%). Avapro/Avalide sales were down 23% to $195 million. Abilify sales were $737 million (+4%). Reyataz sales were up 11% to $416 million. Sustiva Franchise sales were $412 million (+14%). Baraclude sales were up 20% to $318 million. Sprycel sales were up 34% to $227 million. Onglyza/Kombiglyze sales were $153 million (+112%). R&D expenses remained flat at $1.0 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters